Overview
Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
AAE581 is a specific inhibitor of the cysteine protease cathepsin K. This trial is designed to provide detailed information about the effects( efficacy and safety) of AAE581 on Bone Mineral Density.Phase:
Phase 2Details
Lead Sponsor:
Novartis Pharmaceuticals
Criteria
Inclusion Criteria:- Low spine Bone Mineral Density
- 0 to 1 prevalent fracture in non lumber spine
Exclusion Criteria:
- History or presence of any bone disease other than osteopenia /osteoporosis
- Previous treatment with other anti-osteoporosis agent(Wash out required)
- Evidence of vitamin D deficiency
Other protocol-defined inclusion/exclusion criteria may apply.